Articles by Anna Rose Welch
-
Could 96 Percent FDA Drug Approval Rate Harm Biosimilar Market?
9/1/2015
Last week, Matthew Herper of Forbes published an eye-opening article providing a closer look at FDA approvals in recent years, coming to the conclusion that the industry is facing what could be a dangerously high approval rate for new drugs. But how could high approval rates be a bad thing?
-
FDA News Roundup: Otsuka, AstraZeneca, Ipsen, And More
7/17/2015
What FDA decisions have you missed recently?
-
Venture Philanthropy: Is It Really Promoting Patient Centric Drug Development?
7/14/2015
Within the last 10 years, a number of nonprofit groups, including the Michael J. Fox Foundation and the Multiple Myeloma Research Foundation, have taken a similar approach to ensuring that their targeted patient populations are being well represented in pharma R&D.
-
FDA News Roundup: Pfizer, Eli Lilly, Vertex, And More
7/10/2015
What FDA decisions have you missed recently?
-
Is Pharma Truly Equipped For Transparency?
7/8/2015
As the call for transparency grows louder in the pharma industry, the question arises: are drugmakers equipped with all they need to be transparent — especially when it comes to demonstrating their drugs’ economic value?
-
Will Biotech Employment Continue To Rise As The Industry Evolves?
6/30/2015
A report from the Bureau of Labor Statistics found that nationwide employment in “pharmaceutical and medicine manufacturing” sunk from 291,795 in 2003 to 277,113 in 2013, The Philadelphia Inquirer reported recently. But it’s not the same story for biotech R&D: employment hit 142,475 in 2013 — up from 135,424 in 2007.
-
3 Steps To Patient Centric Clinical Trials
6/25/2015
Kelly Franchetti, executive director of global patient insights and engagement for Mapi Group, had one big recommendation for pharma at the 2015 Patients As Partners in Clinical Trials conference. According to Franchetti, one of the best ways for pharma to see clinical trials through a patient-centric lens is for those running the clinical trials to recognize themselves, too, as patients.
-
FDA Roundup: Sanofi, Genentech, Apitope, Retrophin, And More
6/11/2015
What regulatory decisions have you missed recently?
-
Will Pay-For-Performance Really Suit The Cancer Drug Space?
6/9/2015
If Express Scripts should have its way, what would happen to inter-industry competition between the pharma players — specifically in the cancer space? If price tags are altered based off a drug’s performance, it seems to me the industry and its ways of quantifying success and leadership in the market will be faced with change as well — but it’s not entirely clear it will be what Express Scripts had in mind.
-
Industry-Academia Partnerships: Is Big Pharma Getting Riskier With Its R&D?
6/3/2015
There’s a new partnership under way in the quest for the long-sought-after cure for HIV. Last month, GSK teamed up with the University of North Carolina at Chapel Hill to form a research institute and a company dedicated to finding a cure for HIV and AIDS. GSK will shell out $4 million annually over the next five years to launch the research center on Chapel Hill’s campus.